Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan

Cancer genomic medicine interprets genetic information for diagnosis and treatment. It requires an organized team of experts from various fields to discuss treatment recommendations at a molecular tumor board (MTB). It is also important to track patient outcomes based on these decisions and seamlessly incorporate them into future discussions at the MTB. We developed a system to manage the MTB efficiently. Using this system, we followed the outcome and prognosis of 1643 patients whose treatment was discussed at the MTB and evaluated the utility of a realistic comprehensive genomic profiling (CGP) test. Treatment recommendations were made for 240 patients (14% of the total cases). Of these, 118 (7% of the total) were treated with the drugs recommended by the MTB. The cancer type with the highest percentage of patients in which treatment recommendations were made and drugs were administered was thyroid cancer, followed by breast cancer, lung cancer, prostate cancer, and cholangiocarcinoma. While cancer-specific overall survival was inconclusive due to few cases, CGP-recommended treatment significantly extended patient survival from the CGP test date. This analysis, utilizing our patient follow-up system, suggests that CGP testing expands treatment options for a subset of patients and may improve treatment efficacy.